WallStreetZenWallStreetZen

NASDAQ: BEAM
Beam Therapeutics Inc Earnings & Revenue

BEAM past revenue growth

How has BEAM's revenue growth performed historically?
Company
520.01%
Industry
165.61%
Market
17.84%
BEAM's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BEAM's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BEAM's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BEAM earnings and revenue history

Current Revenue
$377.7M
Current Earnings
-$132.5M
Current Profit Margin
-35.1%

BEAM Return on Equity

Current Company
-15.9%
Current Industry
-63.6%
Current Market
188%
BEAM's Return on Equity (-15.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when BEAM announces earnings.

BEAM Return on Assets

Current Company
-9.8%
Current Industry
3%
BEAM is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

BEAM Return on Capital Employed

Current Company
-10.46%
Current Industry
19.6%
BEAM has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BEAM vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
BEAM$377.71M-$111.15M-$132.53M+1,103.57%N/A
MOR$259.00M-$41.75M-$206.23M+24.68%N/A
NTLA$36.28M-$472.22M-$481.19M+3.57%N/A
CORT$482.38M$109.00M$105.50M+13.93%+9.43%
MRUS$43.95M-$163.72M-$154.94M+2.75%N/A

BEAM earnings dates

Next earnings date
May 8, 2024

Beam Therapeutics Earnings & Revenue FAQ

What were BEAM's earnings last quarter?

On Invalid Date, Beam Therapeutics (NASDAQ: BEAM) reported Q4 2023 earnings per share (EPS) of $1.91, up 453.7% year over year. Total Beam Therapeutics earnings for the quarter were $142.80 million. In the same quarter last year, Beam Therapeutics's earnings per share (EPS) was -$0.54.

If you're new to stock investing, here's how to buy Beam Therapeutics stock.

What was BEAM's earnings growth in the past year?

As of Q1 2024, Beam Therapeutics's earnings has grown year over year. Beam Therapeutics's earnings in the past year totalled -$132.53 million.

What is BEAM's earnings date?

Beam Therapeutics's earnings date is Invalid Date. Add BEAM to your watchlist to be reminded of BEAM's next earnings announcement.

What was BEAM's revenue last quarter?

On Invalid Date, Beam Therapeutics (NASDAQ: BEAM) reported Q4 2023 revenue of $316.19 million up 1,478.04% year over year. In the same quarter last year, Beam Therapeutics's revenue was $20.04 million.

What was BEAM's revenue growth in the past year?

As of Q1 2024, Beam Therapeutics's revenue has grown 520.01% year over year. This is 354.4 percentage points higher than the US Biotechnology industry revenue growth rate of 165.61%. Beam Therapeutics's revenue in the past year totalled $377.71 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.